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Psychologicalmorbidity is common in chronic respiratory diseases.Thediagnostic accuracy of theHospital Anxiety andDepression
Scale (HADS) and risk factors for comorbid depression in chronic obstructive pulmonary disease (COPD) are addressed.
Consecutive COPD patients (GOLD stage I–IV, 40–75 years old) were enrolled in a multicentre, cross-sectional cohort study.
Diagnosis of depression was ascertained through clinical records. Lung function, HADS score, 6-minute walking test (6-MWT),
MRC dyspnoea score, and COPD Assessment Test (CAT) were evaluated. Two hundred fifty-nine COPD patients (mean age 62.5
years; 32% female; mean FEV1 48% predicted) were included. Patients diagnosed with depression (29/259; 11.2%) had significantly
higher HADS-D and HADS-Total scores than nondepressed patients (median (quartiles) HADS-D 6 [4; 9] versus 4 [2; 7], median
HADS-Total 14 [10; 20] versus 8 [5; 14]). Receiver-operating characteristic plots showedmoderate accuracy forHADS-D, AUC0.662
(95%CI 0.601–0.719), and HADS-Total, AUC 0.681 (95%CI 0.620–0.737), with optimal cut-off scores of >5 and >9, respectively.
Sensitivity and specificity were 62.1% and 62.6% for HADS-D compared to 75.9% and 55.2% for HADS-Total. Age, comorbidities,
sex, and lower airflow limitation predicted depression.TheHADS exhibits lowdiagnostic accuracy for depression inCOPDpatients.
Younger men with comorbidities are at increased risk for depression.
1. Introduction
Depression is a common comorbidity in chronic obstructive
pulmonary disease (COPD) patients [1]. Impaired lung func-
tion is a risk factor for depressionwith up to 4 in 10 respiratory
patients affected [2]. Mood and anxiety disorders in patients
with COPD are likely underdiagnosed [3], emphasising the
need for a reliable and accurate instrument in the recognition
of depression. The Hospital Anxiety and Depression Scale
(HADS [4]) was originally designed by Zigmond and Snaith
in 1983 as a short, easy-to-use, 14-item screening tool for
depression and anxiety symptoms in the hospital outpatient
setting [5]. It is composed of two 7-item subscales (HADS-D
and HADS-A for depression and anxiety, resp.) both ranging
from 0 to 21 with higher scores indicating more severe
distress. Items enquire about symptoms over the preceding
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week and are self- or clinician-rated on a 4-point Likert scale.
The developers suggested categorising subjects according to
subscale score into noncases (0 to 7), possible cases (8 to 10),
and probable cases (>10) of clinical depression [4].
A 1997 review found both subscales to be reliable and
valid measures for assessing anxiety and depression symp-
toms in medical patients in European, American, and Asian
cohorts [6]. An updated analysis in 2002 found similar
results in general medical, psychosomatic, and psychiatric
patients with an optimal cut-off score of ≥8 for both sub-
scales to define patients with probable diagnosis of depres-
sion or anxiety [7]. However, classifying patients as either
depressed/anxious or not according to HADS threshold
scores is controversial, especially so in chronic disease. A
range of cut-offs has been used, for example, HADS-D >4
in coronary heart disease [8], HADS-D >7 in cancer [9],
and HADS-D >11 in end-stage renal disease [10]. Its original
purpose as a screening tool notwithstanding, in these studies,
categorisation according to HADS scores is often implicitly
used to diagnose depression.
The HADS has frequently been used in patients with
COPD, among other reasons to assess psychological health
status [11], quality of life [12], and effectiveness of pulmonary
rehabilitation [13]. In spite of its widespread use, the HADS’
diagnostic accuracy in COPD patients has only been exam-
ined in a small sample for anxiety [14]: in 55 COPD patients,
of whom 14 were clinically diagnosed with an anxiety dis-
order, the optimal HADS-A cut-off score of ≥4 achieved
moderate diagnostic power. However, no validation of the
HADS for diagnosing depression in COPD patients has yet
been attempted although the aforementioned results indicate
that optimal cut-off scores for chronic disease patients are
likely to differ from those originally suggested for the general
patient population.
The aim of the current cross-sectional study was to
validate the use of the HADS in screening patients with
COPD for the presence of clinically diagnosed depression.
We furthermore explored the role of patient and disease-
specific predictors for depression. Data were extracted from
the baseline assessment of an ongoing longitudinal COPD
cohort study in Switzerland.
2. Patients and Methods
2.1. Study Subjects. Inclusion criteria were an objective diag-
nosis of COPD according to GOLD guidelines [15] and age
between 40 and 75 years. Exclusion criteria were mental or
physical disability precluding informed consent or protocol
compliance, as well as acute or recent (within the preceding
six weeks) exacerbation of COPD.
2.2. Study Design. The Obstructive Pulmonary Disease Out-
comes Cohort of Switzerland (TOP DOCS) is an ongo-
ing prospective observational cohort study coordinated by
the University Hospital of Zurich, Switzerland, involving
patients with mild to very severe (GOLD stage I to IV)
COPD examined annually for at least three years each.
Recruitment involves seven hospitals in Switzerland. A range
of demographic, COPD-specific, physiologic, and quality
of life-related variables are recorded. At baseline patients
attending participating clinics consented andwere enrolled in
a nonselective, consecutive manner. The study was approved
by the Ethics Committee of theCanton of Zurich, Switzerland
(Kantonale Ethikkommission Zu¨rich), registration reference
KEK-ZH-Nr. 2011-0106.
2.3. Measurements. Patients’ characteristics and clinical
information were ascertained through self-report question-
naires, investigator-led interviews, and clinical records. Apart
from details extracted from detailed clinical records, all
assessments were conducted by either trained pulmonolo-
gists or dedicated study investigators.
Information about the presence or absence of an active
diagnosis of unipolar depression according to ICD-10 [16]
was extracted from patients’ clinical records and double-
checked by personal communication with patients’ physi-
cians. Most diagnoses had been made by primary care
physicians (who are required to apply ICD-10 coding criteria
to receive reimbursement from patients’ health insurance
providers). Whilst this precluded the uniform use of rigorous
psychiatric interviews, the approach is an adequate reflection
of clinical reality.
The German language version of the HADS [4] was
administered as a self-rated questionnaire for patients to
fill in either during the recruitment visit or as soon as
possible thereafter. Both the HADS-A and HADS-D 7-item
components were administered (each ranging from 0 to
21 with higher scores indicating increased symptoms) to
evaluate patients’ perceived psychological distress.
Forced expiratory volume in one second (FEV1) andmax-
imum forced vital capacity (FVC) were assessed according
to the criteria for reproducibility of the American Thoracic
Society [17]. COPD-specific assessments included the 6-
minute walking test (6-MWT; maximum distance in meters
walked in six minutes) [18], Medical Research Council
(MRC) Dyspnoea score (ranging in ascending severity from
0 to 4) [19], COPD assessment test (CAT; an 8-item health-
related quality of life questionnaire ranging from 0 to 40
with higher scores indicating more severe impairment) [20],
and BODE index (the composite of body mass index (BMI,
body weight in kilograms divided by body height in meters
squared), FEV1% predicted, 6-MWT, and MRC Dyspnoea
scale; ranging from 0/low risk to 10/high risk) [21].
2.4. Analysis. Receiver operating characteristic (ROC)
curves [22] and area under the curve (AUC) statistics were
compared for HADS-D and HADS-total [23]. DeLong et
al.’s [24] approach for estimating ROC parameters, Hilgers’
[25] nonparametric 95% confidence interval (CI) estimation
method for criterion values, and Youden’s [26] index 𝐽 (the
maximum vertical distance between the diagonal guessing
line and the ROC curve) were estimated alongside likelihood
ratios (LR). A clinical diagnosis of depression at the time
of assessment was the reference standard. Multivariable
logistic regression models for depression with stepwise
predictor selection were constructed including HADS, age,
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348 COPD patients screened for
eligibility
∙ Refused participation (71)
∙ Language difficulties precluding
informed consent (6)
271 COPD patients eligible and
∙ Did not attend (8)
263 COPD patients attended
∙ Incomplete data (4)
259 COPD patients with complete
data for HADS and depression
status
consented
Figure 1: Flowchart of chronic obstructive pulmonary disease
(COPD) patients in the study.
gender, BMI, FEV1%, number of comorbidities, 6-MWT,
and MRC-dyspnoea (chosen as established risk factors for
depression in COPD [3, 27, 28]). CAT score was added
to control for nonspecific COPD-related quality of life
impairment and antidepressant use was included to adjust
for treatment-related confounding. Model assumptions were
tested via Kolmogorov-Smirnov tests and residual plots.
Independent sample 𝑡-tests, Mann-Whitney 𝑈 tests, and
Chi-Square statistics were Bonferroni-corrected for multiple
testing (nominal 𝑃 < 0.05). Analyses were performed using
MedCalc for Windows, version 12.6.1 (MedCalc Software,
Ostend, Belgium).
3. Results
Figure 1 depicts the flow of all 263 participants enrolled
between October 2009 and June 2013 from screening to anal-
ysis. Four patients were excluded due to missing data, leaving
259 COPD patients who provided complete information for
HADS score and depression status. The prevalence of active
depression according to ICD-10 was 11.2% (29/259). Among
depressed patients, 35% (10/29) had been prescribed an
antidepressant. Patient characteristics are displayed inTable 1.
There were no significant differences between depressed
and nondepressed patients with respect to demographic and
disease-related characteristics although there was a trend for
worse airflow limitation and more severe GOLD stage in
nondepressed patients.
Patients with a preexisting diagnosis of depression had
significantly higher HADS-D scores than nondepressed
Table 1: Sample characteristics.
Variable Not depressed(𝑛 = 230)
Depressed
(𝑛 = 29) 𝑃 value
†
Female, 𝑛 (%) 70 (30.4%) 14 (48.3%) 0.085
Age, mean (SD) 62.7 (7.5) 60.0 (8.3) 0.057
BMI, mean (SD) 26.4 (6.1) 26.1 (5.9) 0.808
Comorbidities, mean (SD) 2.4 (2.2) 3.1 (1.6) 0.061
Diabetes mellitus, 𝑛 (%) 32 (13.9%) 1 (3.4%) 0.195
OSA, 𝑛 (%) 21 (9.1%) 5 (17.2%) 0.298
Arterial hypertension, 𝑛 (%) 109 (47.4%) 15 (51.7%) 0.808
Malignancy, 𝑛 (%) 27 (11.7%) 3 (10.3%) 0.931
GOLD stage, 𝑛 (%)††
I 17 (7.4%) 2 (6.9%)
0.035
II 74 (32.2%) 16 (55.2%)
III 87 (37.8%) 10 (34.5%)
IV 52 (22.6%) 1 (3.5%)
CAT, mean (SD) 15.7 (7.1) 17.4 (7.4) 0.213
BODE index, mean (SD) 3.4 (2.4) 2.8 (2.3) 0.203
MRC-dyspnoea, mean (SD) 1.7 (1.1) 1.8 (1.0) 0.736
FEV1%, mean (SD) 46.6 (20.7) 54.5 (21.2) 0.044
6-MWT (meters), mean (SD) 412 (131) 410 (124) 0.916
†Frequencies and means were compared using 𝜒2-tests and independent 𝑡-
tests, respectively.
††
𝜒
2-test for the frequency distribution across GOLD stages I/II/III/IV in
depressed versus nondepressed patients.
6-MWT: 6-minute walking test; BMI: body mass index; CAT: chronic
obstructive pulmonary disease assessment test; CPAP: continuous positive
airway pressure; FEV1%: percentage of predicted forced expiratory volume
in one second; GOLD: global initiative for chronic obstructive pulmonary
disease; MRC-dyspnoea: Medical Research Council dyspnoea scale; OSA:
obstructive sleep apnoea.
patients: median ± quartiles 6 (4; 9) for depressed versus 4
(2; 7) for nondepressed subjects (𝑃 = 0.004). The same held
true for the HADS-total score: median ± quartiles 14 (10;
20) for depressed versus 8 (5; 14) for nondepressed patients
(𝑃 = 0.002).
Figure 2 depicts the ROC curve for theHADS-D subscale.
The overall discriminant performance was low but signif-
icantly different from random chance, AUC 0.66 (95% CI
0.60–0.72). Youden’s index 𝐽 identified a threshold of HADS-
D >5 as the optimal cut-off score to diagnose depression
(𝐽 = 0.25). A cut-off >5 yielded a sensitivity of 62.1% (95% CI
42.3%–79.3%), a specificity of 62.6% (95% CI 56.0%–68.9%),
a positive LR of 1.66 (95% CI 1.2–2.3), and a negative LR of
0.61 (95%CI 0.4–1.0). Using a cut-off value of 5 on theHADS-
D applied on the background of an observed prevalence
for depression of 11.2% yielded a positive predictive value
of 17.3% and a negative predictive value of 92.9%. Thus, in
100 hypothetical patients with a HADS-D >5, 17 will qualify
for a diagnosis of depression, whilst among 100 patients
with a score ≤5, on average 93 will be correctly identified
as nondepressed. The comparison between HADS-D and
HADS-total ROC plots is shown in Figure 3. There was no
significant difference in overall performance between both
scores, AUCHADS-D 0.662 versus AUCHADS-total 0.681 (95%
CI for the difference 0–0.070). The optimal cut-off score for
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Figure 2: Receiver operating characteristic (ROC) curve for the
HADS-depression subscale. Solid triangles indicate different cut-off
scores for diagnosing depression.
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Figure 3: Comparative receiver operating characteristic (ROC)
curves for HADS-depression (solid triangles) and HADS-total
(white triangles).
diagnosing depression on the HADS-total was >9, Youden’s
𝐽 = 0.311, sensitivity 75.9% (95% CI 56.5%–89.7%), and
specificity 55.2% (95% CI 48.5%–61.8%).
The stepwise logistic regression model identified four
significant predictors (model fit 𝑃 < 0.001). An increasing
likelihood of suffering from depression was predicted by
lower age (𝑃 = 0.010), higher number of comorbidities (𝑃 =
0.004), male gender (𝑃 = 0.016), and higher percentage of
predicted FEV1 (𝑃 = 0.047). This model correctly classified
89.6% of cases. Controlling for antidepressantmedication use
did not alter the results. Thus, younger men with additional
comorbidities had the highest risk of depression.
4. Discussion
In this cross-sectional multicentre cohort study involving
patients with mild to very severe COPD, we found low
accuracy of both theHADS-D andHADS-total in identifying
patients with a preexisting diagnosis of depression. As the
optimal cut-off HADS-D >5 yielded a positive predictive
value of only 17.3% and a negative predictive value of 92.9%,
the test seems to more accurately identify the absence rather
than presence of depression. Its usefulness as a general mea-
sure of psychological distress notwithstanding, the validity
of the HADS-D as a tool for classifying COPD patients
into depressed and nondepressed categories—as commonly
applied in previous studies—is questionable. This lack of
discriminant power may be explained in part by the original
validation of the questionnaire, which was aimed at a general
medical case mix in an outpatient setting, rather than at
secondary/tertiary care patients with chronic debilitating
ailments. Yet, despite caveats mentioned by the HADS’
developers [5], over the last three decades it has been applied
to the evaluation of depression and anxiety symptoms in a
large variety of clinical contexts outwith its original target
group. Relying on a one-week retrospective questionnaire-
based approach to classify patients as depressed or not for
ensuing subgroup analyses (e.g., to predict physical activity
[29]) is not appropriate. Moreover, the original purpose of
the HADS as a screening rather than diagnostic tool should
forbid reliance on its results as the sole indicator of clinically
significant depression—a labelling approach applied in previ-
ous research. This study reemphasizes that the HADS should
not be used to diagnose depression or reliably subgroup
patient samples.
Our results on depression in COPD patients are in
line with findings from a recent meta-analysis in cancer
and palliative care patients [30], which reported a weighted
combined sensitivity of 71.6% with a specificity of 82.6% of
the HADS for identifying depression. Restricting analyses
to trials using HADS-D >7 as cut-off yielded a sensitivity
of 68.3% with a specificity of 85.7%. The authors of the
meta-analysis promote the use of the HADS as a screening
rather than diagnostic tool. High subscale correlations may
favour using the HADS as a general measure of psychological
distress rather than specifically detecting depression and
anxiety [31–33]. Furthermore, studies vary substantially in
cut-offs used to identify mental morbidity, casting doubt
on the HADS’ usefulness as a screening tool [34]. Using
recommended cut-off scores may underestimate psychiatric
morbidity in cancer patients [35].
A review incorporating all studies (2000 to 2010) inves-
tigating the HADS’ factor structure found heterogeneous
results: only half of the included trials confirmed the two-
factor model (depression and anxiety), whilst others iden-
tified between one and four underlying constructs [31]. For
example, an established alternative model suggests three fac-
tors labelled, respectively, “negative affectivity,” “anhedonic
depression,” and “autonomic anxiety” [32]. Yet, a 2013 meta-
confirmatory factor analysis favoured the depression/anxiety
two-dimensional structure [33]. Given the confusing theory
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underpinning the HADS, its use as a measure of any specific
psychiatric disorder should best be avoided.
Consequently, the inconsistency of the HADS’ factor
structure across samples [31], the discrepancy between its
wordings based on colloquial British expressions, and its
international application [36], compounded by the exclusion
of somatic items, have led to calls for abandoning the 30-
year-old HADS in favour of more accurate instruments
[37]. Others continue to promote the HADS as a valid,
cross-culturally appropriate tool for assessing psychologi-
cal distress [38]. Future studies should make an effort to
validate psychiatric diagnoses in line with the best clinical
practice.
The prevalence of depression according to ICD-10 in
our cohort (11.2%) was lower than in other studies with
reported rates of up to 42% [27]. However, considering only
studies based on a definition of depression according to
established classification systems yields a lower estimate of
about 20% [39]. Another explanation for the low prevalence
of depression may be the homogeneous composition of our
cohort composed of well looked-after patients recruited from
established high-quality care centres in Switzerland. The
observed higher rate of diagnosed depression in younger
patients with better airway function could be due to a lower
threshold for seeking professional help for psychological
issues in more recent generations. Less physically limited
patients may be more inclined to recognising and address-
ing ailments other than pulmonary disease. Alternatively,
clinicians’ thresholds for diagnosing depression could be
different in these patients. Many factors may contribute to
emotional morbidity in COPD patients, including social
isolation and dependence on others for activities of daily
living [28]. Crucially, however, feelings of low mood and the
general psychological impact of chronic disease must not be
equated with a psychiatric diagnosis of a depressive disorder.
The HADS gauges psychological impairment but is not
suited as a diagnostic tool. Investigators need to be cautious
about labelling subjects inappropriately. As confirmed by our
results, overreliance on a self-report questionnaire is prone to
erroneous categorisation of patients.
There are some limitations to our study. The recruit-
ment context of specialist pulmonary care necessitated
the evaluation of preexisting rather than newly diagnosed
depression. Whilst recorded diagnoses of depression were
double-checked with patients’ registered clinicians, short-
term variations in mood may have hampered the HADS’
ability to detect long-term impairment. Yet, as many clinical
trials have used the HADS to label patients as depressed
or not irrespective of any reference standard, our findings
carry significant implications for the planning of future trials.
The comparatively low prevalence of depression, potentially
contributed to by underdiagnosis, may have limited the
statistical power. Nonetheless, our large nonselective sample
is representative of the COPD patient population in Switzer-
land and is consequently characterised by a high socioe-
conomic status and low proportion of ethnic minorities—
both factors that have been linked to low rates of depression
[40].
5. Conclusions
In this large cross-sectional study of stable COPD patients,
the HADS questionnaire had a low accuracy in identifying
a diagnosis of depression. This is the first study to address
HADS-D test accuracy in COPD patients. Depression rates
were highest among young male patients with additional
comorbidities. The clinical implications of our findings are
twofold. Firstly, the HADS should not be used as a stand-
alone diagnostic tool for depression in COPD patients.
It provides an appropriate scale to evaluate psychological
distress but does not allow for diagnostic classification.
Secondly, clinicians’ awareness of the significant prevalence
of psychological comorbidities in chronic pulmonary disease
patients needs to be improved.
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